Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
about
Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy.Ifosfamide-induced Encephalopathy Precipitated by Aprepitant: A Rarely Manifested Side Effect of Drug Interaction.Aprepitant: drug-drug interactions in perspective.Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.Neurological complications of transplantation: part I: hematopoietic cell transplantation.Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice.Aprepitant and fosaprepitant drug interactions: a systematic review.Two cases of fatal encephalopathy related to Ifosfamide: an adverse role of aprepitant?Aprepitant-associated ifosfamide neurotoxicity.Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation.High-dose thiotepa-related neurotoxicity and the role of tramadol in children.Ifosfamide-induced encephalopathy due to a novel formulation of ifosfamide.The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
P2860
Q37606033-AFAFD696-0CC3-47A5-9994-B13ED51A14A4Q37725989-11E51D36-C7E9-420C-A1B6-7079B0FEF5F7Q37757799-3E340D6A-C6AA-42D4-AC84-570FBE49A302Q37854702-497DD56D-5844-4FCC-AC53-C93602B5621DQ38132157-B12EC6ED-E067-4628-ACCF-E533BF4E0A4EQ38752456-EBF97A63-EB53-49C1-BA7F-91040E27D38EQ39282847-2078B0C8-23E6-40F1-97D1-259BB8EA656CQ41994672-7F1660D0-92B2-40C3-B8A4-F74FD827464AQ43275693-99F544A5-CD15-40CB-929E-471C23E59D3EQ45169488-537182F6-CB47-43D1-A8F2-004F286863ACQ50046503-918C54A4-EA35-4296-8323-EEC32A9DF0BFQ52148939-A5B7BE98-6A2F-4C34-81D7-E7ABE92CD609Q53910447-D93DA5D6-2232-4DFA-A5AF-407CA3D39C5F
P2860
Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Characterization of the occurr ...... y with concomitant aprepitant.
@en
Characterization of the occurr ...... y with concomitant aprepitant.
@nl
type
label
Characterization of the occurr ...... y with concomitant aprepitant.
@en
Characterization of the occurr ...... y with concomitant aprepitant.
@nl
prefLabel
Characterization of the occurr ...... y with concomitant aprepitant.
@en
Characterization of the occurr ...... y with concomitant aprepitant.
@nl
P2093
P2860
P356
P1476
Characterization of the occurr ...... y with concomitant aprepitant.
@en
P2093
Amy Hatfield Seung
Audrea H Szabatura
Joshua E Howell
Suzanne A Nesbit
P2860
P304
P356
10.1177/1078155208093930
P577
2008-09-01T00:00:00Z